




版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
Chapter12ChengYangCoagulationandAnti-coagulationImbalanceChapter12ChengYangCoagulatioIntroductionvasospasm血管痙攣thrombosis血小板血栓形成fibrinclotformation纖維蛋白凝塊形成anticoagulationsystemfibrinolyticsystemcoagulationsystem抗凝凝血纖溶hemostasis(止血)Introductionvasospasm血管痙攣throm(I)Coagulationsubstances:platelets&coagulationfactors
Coagulationfactors ProductionsourceFactorI(fibrinogen)LiverFactorII(prothrombin) LiverFactorIII(tissuefactor)TissueFactorIV(Ca2+)FactorVLiverFactorⅥ(obsolete=factorVa)FactorVIILiverFactorVIIIEndothelialcellsFactorIXLiverFactorXLiverFactorXILiverFactorXIILiverFactorXIIIPlatelets I.CoagulationSystemandItsFunction(I)Coagulationsubstances:pla粘附(adhesion):VECinjury→collagenexpose內(nèi)皮下膠原暴露combinationofpltandcollagenactivatedcollagen,thrombin,ADP,TXA2,platelets粘附(adhesion):VECinjury→collag聚集(aggregation):——combinationbetweenpltrest→noaggregationstimuli→aggregation→extendpseudopods(偽足),degranulation(血小板脫顆粒)聚集(aggregation):——combinationScanningelectronmicrographofmoderatelyactiveplateletPseudopodsScanningelectronmicrographothrombosisplateletadhesionplateletaggregationthrombosisplatel
(II)Coagulationpathways:
1.Extrinsiccoagulationpathway
maincoagulationpathwayinitialstimulusinthiscascadeistissue-basedtissuefactor(TF,factorIII):alipid-richproteinmaterial
Initialfactor:FIII(tissuefactor,TF)tissuefactor+phospholipid+Ca2++factorVIIcanactivatefactorsIXandX.FXathenactivateFII(prothrombin)FIIa(thrombin)cleavesfibrinogen(I)tofibrin(Ia)(II)Coagulationpathways:ExtrinsicPathwayforBloodClottingTissuefactorⅩProthrombinactivatorprothrombinthrombinⅦaⅦⅩaCa2+TissuedamageCa2+Phospholipid(platelet)ⅤaCa2+fibrinogenfibrinⅧaⅤⅧExtrinsicPathwayforBloodCl2.IntrinsiccoagulationpathwayFXII:aprotease(intrinsictotheblood)Initialfactor:FXIIconvertsFXItoFXIaconvertsFIXtoFIXa“phospholipids+Ca2++FXa+FVa”complex(prothrombinactivator)convertsprothrombintothrombincleavesfibrinogenintofibrin2.IntrinsiccoagulationpathwaphospholipidIntrinsicPathwayforBloodClottingfibrinⅩaⅩⅫaⅫⅪaⅪⅨaⅨCa2+ⅧaⅧCa2+prothrombinthrombinProthrombinactivatorⅤⅤaCa2+VECinjuryCa2+fibrinogenplateletphospholipidIntrinsicPathway1.FX→FXa
prothrombinactivatorformation凝血酶原激活物的形成2.prothrombin(FII,凝血酶原)→thrombin(FIIa,凝血酶)3.fibrinogen(Fbg,FI,纖維蛋白原)→fibrin(Fbn,FIa,纖維蛋白)threestagesforcoagulation:1.FX→FXathreestagesforcoag1.Humoralanticoagulationsystem:AnticoagulantfactorsProductionsourceTFPIendothelialcellHeparinLiverAntithrombinIII(AT-III)LiverProteinC(PC)LiverProteinS(PS)LiverPlasminogen LiverFDPIII.AnticoagulationSystem1.HumoralanticoagulationsystheparinTFPI+FⅩa-TFPIcomplexFⅩa-TFPI-FⅦa-TFcomplexTissueFactorPathwayInhibitor(TFPI,組織因子途徑抑制物)Ca2+,XaⅦ,XinactivationVECTFPIheparinTFPI+FⅩa-TFPIcomplexFⅩVEC(內(nèi)皮細(xì)胞)PCAPCFⅤa,F(xiàn)ⅧainactivationPS++血栓調(diào)節(jié)蛋白TMthrombin凝血酶TM-ProteinCSystem(血栓調(diào)節(jié)蛋白-蛋白C系統(tǒng))thrombinprothrombin凝血酶原VEC(內(nèi)皮細(xì)胞)PCAPCFⅤa,F(xiàn)ⅧaPS++血栓調(diào)節(jié)蛋AntithrombinⅢ&Heparin(抗凝血酶III,肝素)ClearthrombinAT-ⅢclearIIa,VIIa,IXaXIa,Xa,XIIaAT-ⅢheparinX100AntithrombinⅢ&Heparin(抗凝血酶I2.Cellularanticoagulationsystem
monocyte-macrophagesystem&hepatocytecanclearandremoveprocoagulants(endotoxin,Ag-Abcomplex,etc)activatedcoagulationfactors(TF)prothrombinactivatormonomeroffibrincanactivateendogenousanticoagulationsubstancesfibrinolyticsystem2.Cellularanticoagulationsys
Function
dissolvingthethrombusthathasalreadyformedinvessels
使纖維蛋白凝塊溶解,保證血流通暢,也參與組織的修復(fù)和血管的再生等III.FibrinolyticSystemVECandtissueinjuryplasminplasminogenfibrinogenFDPTPA(tissueplasminogenactivator)ⅫaProcess1.Humoralplasminogenactivators:XIIa→plasmaproactivator2.Tissueplasminogenactivators(TPA):
anoxia,stasis,tissuedamage,andfibrindeposition→VECandtissueinjuryurokinaseandstreptokinase:artificialplasminogenactivatorsFunctionIII.FibrinolyticSyssolublecanhydrolyzefibrinogenandmanycoagulationfactorsanticoagulationeffect
fibrindegradationproducts,FDP,纖維蛋白降解產(chǎn)物solublefibrindegradationprodDisseminatedIntravascularCoagulation,DICDisseminatedIntravascularCoaI.ConceptofDIC
DICisapathologicalsyndromecharacterizedbybleeding,Bp↓orshock,multipleorgandysfunction(embolism)andanemia,whichresultsfromthedisturbanceofkineticbalanceofcoagulationandfibrinolyticprocesses(hypercoagulable→hypocoagulable).causes→extensiveactivationofclottingfactors(hypercoagulablestate)→↑c(diǎn)onsumptionofclottingfactorsandplatelet,depositionoffibrinandsecondaryfibrinolysis(hypocoagulablestate)→bleeding,Bp↓orshock,multipleorgandysfunction(embolism),anemiaI.ConceptofDICDICi[醫(yī)學(xué)]DIC彌散性血管內(nèi)凝血課件[醫(yī)學(xué)]DIC彌散性血管內(nèi)凝血課件Waterhouse-FriderichsensyndromeadrenalnecrosisWaterhouse-FriderichsensyndroMeningococcemia(腦膜炎球菌血癥)onthecalves(小腿)Meningococcemia(腦膜炎球菌血癥)onthMeningococcemiaassociatedpurpuraMeningococcemiaassociatedpur(I)Etiology1.Infection(mostcommon):
bacteriaandtheirtoxins,fungi,viruses,rickettsiae;tuberculosis,abscesses,osteomyelitis
2.Malignancy:
acutepromyelocyticleukemia,acutemonocyticleukemia,disseminatedprostaticcarcinoma;lung,breast,gastrointestinalmalignancy
3.Obstetricalcomplications:
abruptionplacenta,abortions,amnioticfluidembolism,hemorrhagicshock;deadfetussyndrome
4.Trauma&largeoperation:
massivetissuedestruction,braindamage,massiveburn,organtransplantation5.Vasculardisease:
braininfarctionorhemorrhage;aorticaneurysm,gianthemangioma
6.Others:
heparin-inducedthrombocytopeniawiththrombosis(HITT)purpurainnewborns(homozygousproteinCdeficiency)II.EtiologyandPathogenesisofDIC(I)Etiology1.Infection(most[醫(yī)學(xué)]DIC彌散性血管內(nèi)凝血課件
TFreleaseandactivationofextrinsiccoagulationtrauma,burn,largeoperation(12.7-15%),obstetriccomplications(8.6-20%)malignanttissuenecrosis(20-28.3%),leukemiacellinjury(II)Pathogenesis→FIII(tissuefactor)releaseintoblood→extrinsiccoagulation(+)TFreleaseandactivationofsiteactivityofTF(μ/mg)
liver10
muscle20
brain50
lung50placenta2000Q:為什么產(chǎn)婦容易發(fā)生DIC?siteactivactivateFⅫ→intrinsiccoagulation(+)VECinjury→releaseTF→extrinsiccoagulation(+)anticoagulanteffect↓NO、PGI2、ADPaseproduction↓→↓inhibitioneffectofPLTadhesionandaggregationvascularendothelialcellsdamageandcoagulationandanticoagulationimbalancesevereinfectionandendotoxemia;severeacidosis;persistenttissueischemiaandhypoxia;strongimmunereactions→Ag-AbcomplexCauses:Mechanism:activateFⅫ→intrinsiccoagulexcessivedestructionofbloodcellsandactivationofplateletssevereRBCdestruction:transfusionofincompatiableblood,acutehemolyticreactions→RBCinjury→*absorbVII,IX,Xandprothrombintoacceleratecoagulation*releaseofADPandPF3→initiateaplateletreleasereaction→adhesion&aggregationofplateletexcessivedestructionofb[醫(yī)學(xué)]DIC彌散性血管內(nèi)凝血課件
WBCdestruction:acutepromyelocyticleukemia,chemotherapytreatment→WBCinjury→aTF-likeagentrelease→extrinsiccoagulationtriggeredbacterialsepsis→endotoxin,IL-1,TNF-αrelease→extrinsiccoagulationtriggeredWBCdestruction:Destructionoractivationofplatelets:
endotoxin,antigen-antibodycomplex→damageplatelets→releaseofPF3,PF4,β-TGPF3:canacceleratetheactivationofprothrombinPF4:canneutralizetheactionofheparinβ-TG:canpromotethecoagulationofbloodDestructionoractivationofpacutenecroticpancreatitis→releaseoftrypsin(enzyme)→convertingprothrombintothrombinsnakevenom→activationofFX,FV,prothrombin;conversionoffibrinogentofibrinmetastaticcancercells→secreteprocoagulantsubstancesamnioticfluidembolism→TF-likeagentreleasetrauma,burns,viruses→activationofFX→coagulationsystem(+)Ag-Abcomplex→activationofFXII→coagulationsystem(+)bacteria(endotoxins)→activationofTF
Pro-coagulantsenteringcirculationacutenecroticpancreatitis→ExcessiveclottingInfectionCancerChildbirth,deadfetus,orsurgerySevereheadinjuryPoisonoussnakeClottingfactorsandplateletsaredepletedExcessivebleedingoccursEndothelialdamage;tissuedamage;directoractivationoffactorX,damageofbloodcellsHypercoagulablestageHypocoagulablestageSecondaryfibrinolyticstageExcessiveclottingInfectionCan
Inappropriatelyconditionedmonocyte-macrophagessystemIII.PrecipitatingFactorsofDICmonocyte-macrophagesystem:
macrophagesinspleenandtheKupffercellsinliver
Function:removeseveralprocoagulantsubstances(thrombin,fibrin,etc.)removeplasmin,FDP,endotoxin,etc.Necrotictissueandbacteriacanblockitsfunction.InappropriatelyconditionedmExperimentalstudy:
GeneralShwartzmanreaction(GSR,全身性S反應(yīng)):
GSRisaDIC-shocksyndromeaftertwotemporallyspacedintravenousinjectionofsmalldoseofbacterialendotoxins.Theinjectionsofendotoxinscanblockthereticuloendothelialsystem,whichcaninduceDIC.
the1sttime:consumptionofmonocyte-macrophagesystem
the2ndtime:blockadeofmonocyte-macrophagesystem,↓deactivationofendotoxins→bloodcoagultionExperimentalstudy:Liver:clearFIXa,FXa,FXIa,etc.synthesizePC,AT-III,plasminogen,etc.Severehepaticdysfunction↓synthesisofPC,AT-III,plasminogen,etc.inactivationofclottingfactorsdisturbanceshepatocytesnecrosis→TFreleaseLiver:SeverehepaticdysfunctiPregnancy:from3ndweekpregnancy→PLT,FVII,XII,X,IX,V,II,I,etc↑↑AT-III↓Plasminogenactivatorinhibitor(PAI)↑Fibrinolyticactivity↓→bloodcoagulation
mostmarkedintheterminalstageofpregnancyHypercoagulablestatusPregnancy:from3ndweekHyperAcidosis:acidosis→damageVEC→intrinsiccoagulation(+)pH↓→plateletactivity↑→↑aggregationandadhesionofplateletactivityofheparin↓activityofclottingfactors↑→bloodcoagulationAcidosis:shock→bloodflowstasis,aggregationofbloodcells
appearanceofsludgingVasculardisorders:hugeaorticaneurysms,gianthemangiomas(巨大血管瘤)→bloodflowslowdown→
localactivationofcoagulationcascadebleedingtendency→consumptionofplateletandfibrinogenbloodvolume↓→hepaticanticoagulationeffect↓,fibrinolysiseffectdisturbancesMicrocirculationdisordershock→bloodflowstasis,aggresmokingdiabetesintheterminalstageofpregnancysomedrugs(fibrinolyticinhibitors)DecreasedfibrinolyticactivitysmokingDecreasedfibrinolyticIV.StagesofDICstagesbloodclinicalmanifestationshypercoagulablestageclottingfactors↑,PLT↑,productionofmicrothrombiembolismconsumptivehypocoagulablestageplateletandclottingfactorsconsumption↑;firinolyticactivationbleeding,shocksecondaryfibrinolyticstagefibrinolyticactivity↑↑plasminformationFDPformationobviousbleedingIV.StagesofDICstagesbloodcl
Accordingtoclinicalcourse:1.AcuteDIC:developsrapidlyoverseveralhoursorl-2daysunderlyingdiseases:septicemia,shock,severetrauma,etc.2.SubacuteDIC:developsoveraperiodofseveraldaysunderlyingdiseases:malignancies,intrauterinefetaldead,gianthemangiomas,etc.3.ChronicDIC:developsandpersistsovermanyweeksormonthsunderlyingdiseases:malignancy,1iverandkidneydisease,etc.V.ClinicalClassificationofDICAccordingtoclinical
Accordingtocompensatorylevel:
decompensatedcompensatedovercompensated
clotting
consumptionconsumptionconsumptionfactors>production=production<productionDIClevelacute,severeslightchronic,recoverysymptomstypicalnotobviousnottypicallaboratoryclottingfactors↓noobviouschangesclottingfactors↑findingsAccordingtocompensa
DecompensatedDICCompensatedDIC OvercompensatedDIC AcuteDIC Subacute/ChronicDIC ChronicDICClinicaloverseveralhoursaboutoveraperiodofaboutovermanyweekscourseor1-2daysseveraldaystomonthsDepletionvs repletionofDepletion>repletionDepletion=repletionDepletion<repletionclotFactors/PLs
Laboratory↓Clotfactors↑Clotfactors↑Clotfactorsfeatures ↓PLs↑PLs↑PLsClinicalBleeding(+++)Bleeding(+or±)Bleeding(+or±)featuresShock(+++)Shock(-)Shock(-)Thrombo-Emboli(+)Thrombo-emboli(±) Thrombo-emboli(±)CausesSevereviralorbacteriaMalignanciesMalignancyinfectionsIntrauterinefetaldeadLiverandkidneydiseaseTraumaGianthemangiomasIncompatiblebloodtransfusionDecompen
(I)Bleeding(II)Organdysfunction(III)Shock(IV)MicroangiopathichemolyticanemiaVI.Function&MetabolicChangeofDICVI.Function&MetabolicChan
(I)Bleeding:84-88%petechia(皮膚瘀斑)purpura(紫癜)hematemesis(嘔血)melena(黑便)hemoptysis(咯血)hematuria(血尿)rhinorrhagia(鼻出血)colporrhagia(vaginalbleeding,陰道出血)(I)Bleeding:84-88%petechia(腹主動(dòng)脈瘤(abdominalaorticaneurysm)腹主動(dòng)脈瘤(abdominalaorticaneurysMechanismofBleeding:
1.consumptionofcoagulationfactors2.secondaryfibrinolysis3.formationoffibrindegradationproducts(FDPs)(1)inhibitionofplateletaggregation(2)inhibitpolymerizationoffibrinmonomerMechanismofBleeding:(II)
Organdysfunction:“embolism”→MODSevenMOF
lungs,kidneys,brain,heart,liver,spleen,pancreas,GItract,skin,etcrespiratoryfailure——ARDSrenalfailureheartfailurehepaticfailure(II)Organdysfunction:resrenalfailure—renalcortexnecrosisWaterhouse-FriderichsenSyndrome——acuteadrenalfailureSheehan’sSyndrome——pituitarynecrosisrenalfailure—renalcortexne
microthrombiinmyocardiummicrothrombiinlivermicrothrombiinmyocardiummicrothrombiinkidneymicrothrombiinlungmicrothrombiinkidneym(III)Shock↑bloodreturnheart↓peripheralresistance↓vasodilation,capillarypermeability↑histamine,bradykininkinin,complement,fibrinolyticsystem(+)C.O.↓myocardialcontractility↓microthrombiinheartbloodcoagulation↑ECBV↓continuousbleedingconsumptionofclottingfactorsandplateletclottingfactors(+)(III)Shock↑bloodreturn↓peri
(IV)Microangiopathichemolytic
anemia
Theredbloodcellsappearfragmented.Twistedcells,crenatedcells,triangularcells,helmet-shapedcells,andmicrospherocytesareseenonthebloodsmear.Theseabnormalcellsarecalledschistocytes.(IV)Microangiopathichemolyt[醫(yī)學(xué)]DIC彌散性血管內(nèi)凝血課件Mechanismforschistocyte:TheschistocytesresultfromphysicaldamagetotheRBCscausedbytheirpassageamongthelotsofstrandsornetsoffibrin.Mechanismforschistocyte:[醫(yī)學(xué)]DIC彌散性血管內(nèi)凝血課件[醫(yī)學(xué)]DIC彌散性血管內(nèi)凝血課件[醫(yī)學(xué)]DIC彌散性血管內(nèi)凝血課件VII.PathophysiologicalbasisofpreventionandtreatmentofDIC
1.ReversingtheunderlyingdisordersinitiatingDIC:“Treatmentofcausativediseases”septicemia———————————usingantibioticsmalignancies——————————chemotherapyintrauterinefetaldead——————removalofdeadfetustreatmentofshock2.Improvingthemicrocirculation:
Transfusion:increasingtheblood-flowsuitably
Smalldoseofaspirin:inhibitaggregationandadhesionofplatelet
Thrombolysis:streptokinase&urokinase(“plasminogenactivators”)VII.Pathophysiologicalbasis3.Reconstructingthebalanceamongcoagulation,anticoagulationandfibrinolysis:(1)Anticoagulationtherapy:high-doseheparinand/orAT-IIIreplacementtherapyinhypercoagulablestage*administrationofheparinmayleadtoanincreaseinbleeding*(2)Bloodtransfusion:Clottingfactorsreplacement:withfresh,frozenplasma,freshw
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 卵石路面施工方案
- bt項(xiàng)目合同范例
- 上海專利申請(qǐng)代理合同范例
- 農(nóng)村垃圾房建設(shè)合同范例
- 農(nóng)村建房過(guò)戶合同范例
- 中頻爐維修合同范例
- 借款債務(wù)合同范例
- 橋梁圍堰拆除施工方案
- 多粘類芽孢桿菌碳代謝調(diào)控元件開發(fā)及應(yīng)用研究
- 微信平臺(tái)規(guī)則的隱私權(quán)保護(hù)研究
- 2025年廣東廣州市黃埔區(qū)第二次招聘社區(qū)專職工作人員高頻重點(diǎn)提升(共500題)附帶答案詳解
- 第一單元第2課《人工智能應(yīng)用》說(shuō)課稿 2023-2024學(xué)年浙教版(2023)初中信息技術(shù)八年級(jí)下冊(cè)
- 2025年寫人要抓住特點(diǎn)
- 數(shù)字化轉(zhuǎn)型賦能制造業(yè)企業(yè)高質(zhì)量發(fā)展
- 深筋膜徒手松解療法
- 皮膚病學(xué)測(cè)試題含參考答案
- 《社會(huì)支持理論》課件
- 人工智能教育應(yīng)用的倫理風(fēng)險(xiǎn)及其應(yīng)對(duì)方案
- 幼兒園大班健康活動(dòng)《愛(ài)護(hù)眼睛保護(hù)視力》課件
- 川教版四年級(jí)《生命.生態(tài).安全》下冊(cè)全冊(cè) 課件
- 醫(yī)院品管圈(QCC)活動(dòng)成果報(bào)告書-基于QFD 潤(rùn)心服務(wù)改善 ICU 患者及家屬就醫(yī)體驗(yàn)
評(píng)論
0/150
提交評(píng)論